Docket #0626 Date Filed: 09/04/2024

MCKOOL SMITH, PC
John J. Sparacino (TX Bar No. 18873700)
S. Margie Venus (TX Bar No. 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile: (713) 485-7344
Email: jsparacino@mckoolsmith.com
Email: mvenus@mckoolsmith.com

Travis E. DeArman (TX Bar No. 24074117)
300 Crescent Court, Suite 1200
Houston, Texas 75201
Telephone: (214) 978-4000
Facsimile: (214) 978-4044
Email: tdearman@mckoolsmith.com

PORZIO, BROMBERG & NEWMAN, P.C.
Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
Brett S. Moore (admitted *pro hac vice*)
100 Southgate Parkway
P.O. Box 1997
Morristown, New Jersey 07962-1997
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
Email: WJMartin@pbnlaw.com
Email: RAParisi@pbnlaw.com
Email: BSMoore@pbnlaw.com

Counsel for the Official Equity Security Holders' Committee

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION

In re:	§	**Chapter 11**
	§	
EIGER BIOPHARMACEUTICALS, INC., *et al.*[1]	§	**Case No. 24-80040 (SGJ)**
	§	
	§	
Debtors.	§	**(Jointly Administered)**

THE OFFICIAL COMMITTEE OF EQUITY SECURITY HOLDERS' SUPPLEMENTAL EXHIBIT LIST FOR SEPTEMBER 5, 2024 HEARING

The Official Committee of Equity Security Holders (the "Equity Committee") of Eiger BioPharmaceuticals, Inc., *et al.,* the above-captioned debtors and debtors-in-possession (the "Debtors"), hereby submit this supplemental exhibit list (the "Supplemental Exhibit List") in connection with the matters scheduled for hearing on **September 5, 2024, at 9:30 a.m. (prevailing Central Time)**.

[1] The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Ave., Dallas, Texas 75201.

24800402409040000000000014

EXHIBITS

Ex. No.	Description	Off.	Obj.	Adm.
56	Eiger Press Release dated 09/12/2023			
57	EIGER-EC-00034820 (CONFIDENTIAL)[2]			
58	EIGER-EC-00044769-00044775 (CONFIDENTIAL)[3]			
59	EIGER-EC-00052717-00052732 (CONFIDENTIAL)[4]			
	Any exhibit offered by any other party			
	Any declaration filed by the Debtors (or any other party) in these bankruptcy cases			
	Any pleadings, reports, or other documents filed in the above referenced bankruptcy cases, and any transcripts in any such cases.			
	Any exhibit for impeachment or rebuttal purposes.			

[2] Pursuant to the *Stipulated Confidentiality Agreement and Protective Order* [Docket No. 498/591] this Exhibit is being filed under seal and copies are only being provided to the Debtors and the United States Trustee.

[3] See footnote 2 above.

[4] See footnote 2 above.

Dated: September 4, 2024

Respectfully submitted,

MCKOOL SMITH, PC

/s/ S. Margie Venus
John J. Sparacino (SBN 18873700)
S. Margie Venus (SBN 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile (713) 485-7344
jsparacino@mckoolsmith.com
mvenus@mckoolsmith.com

Travis E. DeArman (SBN 24074117)
300 Crescent Court, Suite 1200
Dallas, Texas 75201
Telephone (214) 978-4000
Facsimile (214) 978-4044
tdearman@mckoolsmith.com

-and-

Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
Brett S. Moore (admitted *pro hac vice*)
PORZIO, BROMBERG & NEWMAN, P.C.
100 Southgate Parkway
P.O. Box 1997
Morristown, New Jersey 07962-1997
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
WJMartin@pbnlaw.com
RAParisi@pbnlaw.com
BSMoore@pbnlaw.com

Counsel for the Official Equity Security Holders' Committee

CERTIFICATE OF SERVICE

I certify that on September 4, 2024, I caused a copy of the foregoing document (excluding Exhibits 57-59 which are being filed under seal) to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas.

/s/ S. Margie Venus
S. Margie Venus

Exhibit 56

Eiger to Discontinue Phase 3 *LIMT-2* Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

Palo Alto, Calif., September 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 *LIMT-2* study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the DSMB recommended the discontinuation of the *LIMT-2* study due to observations of four patients with hepatobiliary events that resulted in liver decompensation.

"The study discontinuation is disappointing, especially for patients with chronic hepatitis delta who have limited treatment options," said David Apelian, MD, PhD, MBA, CEO of Eiger. "We will work closely with FDA and our investigators to conduct an orderly termination of the *LIMT-2* study in the interest of patient safety."

The Phase 3 *LIMT-2* study is an open-label, parallel-arm clinical trial that randomized patients with well-compensated CHD infection to one of two treatment groups: peginterferon lambda 180 mcg QW for 48 weeks with 24 weeks follow-up (Arm 1, n=105), or no treatment for 12 weeks followed by peginterferon lambda treatment for 48 weeks with 24 weeks of follow-up (Arm 2, n=53). In July, the trial completed enrollment of 158 patients in 12 countries across 48 investigator sites.

Dr. Apelian added, "As we look toward the future for Eiger, we will continue to execute on our strategic pivot, announced on June 29 of this year, and seek the financial resources required to advance the Company's development activities on avexitide in hyperinsulinemic hypoglycemia indications. We continue to evaluate strategic partnering options for our virology assets. Eiger is no longer in active discussions with potential partners for a worldwide license for peginterferon lambda."

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and

objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development, including our development activities for avexitide in hyperinsulinemic hypoglycemia indications; our ability to secure financial resources required to advance avexitide in hyperinsulinemic hypoglycemia indications; our ability to identify, pursue and enter into partnering opportunities for our virology assets; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the “Risk Factors” section in Eiger’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Exhibit 57

(Filed Under Seal)

Exhibit 58

(Filed Under Seal)

Exhibit 59

(Filed Under Seal)